National Biologics Facility
Australia's national facility for recombinant protein and biologics, spanning research-grade protein production through to Phase I clinical-grade biomanufacturing. Multi-host expression and end-to-end development for research, industrial and therapeutic use, supporting mAbs, ADCs, radioligand therapeutics, vaccines and beyond, under one ISO 9001 certified quality system.
Discover Our CapabilitiesAustralia's End-to-End Protein Production Capability
The National Biologics Facility (NBF) is Australia's leading facility for recombinant protein and biologics production, spanning research-grade protein supply and clinical-grade biomanufacturing, under an ISO 9001 certified quality management system. NBF operates across two Brisbane sites: the Australian Institute for Bioengineering and Nanotechnology (AIBN) at the University of Queensland, and a new clinical manufacturing suite at the Translational Research Institute (TRI). NBF spans molecular engineering, antibody and nanobody discovery, expression across four host systems (E. coli, Pichia yeast, baculovirus/insect and mammalian), expression optimisation, scale-up bioprocessing, full bioanalytical characterisation, and Phase I clinical-grade manufacturing.
NBF supports all major biologic modalities: monoclonal antibodies (mAbs), bispecifics, antibody fragments and nanobodies, antibody-drug conjugates (ADCs), radioligand therapeutics and radiopharmaceutical precursors, recombinant vaccine antigens, Fc-fusion proteins, therapeutic enzymes, and diagnostic / biomarker proteins. The facility serves academic, industry and government sponsors across the entire translational continuum, from milligrams of difficult-to-express target for early discovery and structural biology, through to grams of clinical-grade drug substance for first-in-human clinical trials. Many programmes are purely research-focused: NBF routinely supplies research-grade and reagent proteins, antigens, and diagnostic and structural-biology targets for research, industrial and therapeutic use, with no requirement to progress to clinical development. Each contract is co-designed with the sponsor, drawing on a frontier suite of expression technologies, custom vector libraries and a multidisciplinary team of protein scientists, bioprocess engineers and analytical specialists. As an NCRIS-funded national facility, NBF combines academic flexibility with industrial-grade quality systems, timelines, and project management for antibody, protein and vaccine manufacture programmes.
NBF News
From clinical trials to landmark partnerships, stay up to date with the breakthroughs and milestones emerging from Australia's leading biologics facility.
View All News
PEF and NBF Unite Under One Banner
Purpose-Built for Protein Production
State-of-the-art laboratories, bioreactors and clean rooms spanning research-grade screening to clinical-grade manufacture
End-to-End Biologics Capabilities
Discovery & Protein Engineering
Antibody and nanobody discovery via phage display, protein engineering, antibody-drug conjugates and bioconjugation strategies.
Molecular Engineering & Cloning
High-throughput cloning, comprehensive vector suite (pOPIN, pET, pGEX, pcDNA, pFastBac) and endotoxin-free plasmid production.
Multi-Host Expression
Four expression platforms, E. coli, Pichia yeast, baculovirus/insect cells and mammalian cells, with parallel optimisation across hosts.
Process Development
Scale-up from shake flask through 10–25 L research bioreactors to 50 L clinical-grade upstream, plus full downstream purification.
Bioanalytics & Characterisation
Identity, purity, intact mass, sequencing, stability, formulation and release-grade assay development across the biologics lifecycle.
Phase I Manufacturing
PC2 clinical-grade drug substance manufacture for first-in-human trials under an ISO 9001 quality management system.
Recombinant protein for research, industry and the clinic
Whether you need a single difficult target expressed for a research project or clinical-grade drug substance for first-in-human trials, NBF delivers recombinant protein at the scale and quality your programme requires, with no obligation to progress to clinical development.
Research & discovery proteins
Research-grade and reagent proteins, antigens for immunisation, and structural-biology and assay targets, from milligram to gram scale across four expression hosts.
Expression systems →Diagnostic & industrial proteins
Diagnostic and biomarker proteins, recombinant enzymes and reference materials for industry and government, produced to consistent, quality-assured specifications.
UQ Resource Centre →Clinical-grade biomanufacturing
Phase I clinical-grade drug substance for first-in-human trials, with master cell banking and release testing under an ISO 9001 quality management system.
Phase I manufacturing →One facility for every biologic modality
From monoclonal antibodies and antibody-drug conjugates to radioligand therapeutics, recombinant vaccines and therapeutic enzymes, NBF's platform supports the full spectrum of biologic modality classes through a single quality system.
From Gene to Clinical Drug Substance
Our integrated pipeline takes targets from gene synthesis and molecular engineering, through multi-host expression screening and scale-up, to Phase I clinical-grade drug substance, within a single facility, single quality system, single team.
A World-Class Team of Scientists & Engineers
Our multidisciplinary team brings decades of combined expertise across protein engineering, multi-host expression, bioprocess scale-up, analytics, project management, and ISO 9001 quality management, translating Australian discoveries from gene to clinical drug substance.
Meet the Team
